A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
AIM ImmunoTech Inc. and its subsidiaries (collectively, “AIM”, “Company”, “we” or “us”) are an immuno-pharma company headquartered in Ocala, Florida, and focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases and immune-deficiency disorders and to treat cancers for which there are currently inadequate or unmet therapies. We have established a strong foundation of laboratory, pre-clinical and clinical data with respect to the development of nucleic acids and natural interferon to enhance the natural antiviral defense system of the human body, and to aid the development of therapeutic products for the treatment of certain cancers and chronic diseases. AIM’s flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (“dsRNA”) molecule being developed for globally important cancers, viral diseases and disorders of the immune system.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 112K | - | - | - | - | - |
| Net Income | -16M | -17M | -29M | -19M | -19M | -14M |
| EPS | $-17.63 | $-30.07 | $-58.20 | $-38.80 | $-38.80 | $-43.65 |
| Free Cash Flow | -13M | -15M | -22M | -16M | -14M | -10M |
| ROIC | -209.5% | -566.8% | -130.1% | -49.2% | -32.6% | -22.8% |
| Gross Margin | 15.2% | - | - | - | - | - |
| Debt/Equity | 0.00 | -6.09 | 0.07 | - | - | 0.04 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -15M | -20M | -32M | -20M | -19M | -15M |
| Operating Margin | -13006.3% | - | - | - | - | - |
| ROE | 0.0% | -388.7% | -283.0% | - | - | -23.5% |
| Shares Outstanding | 3M | 1M | 0M | 1M | 0M | 0M |
AIM ImmunoTech Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
AIM ImmunoTech Inc. (AIM) has a 5-year average return on invested capital (ROIC) of -58.7%. This is below average and may indicate limited pricing power.
AIM ImmunoTech Inc. (AIM) has a market capitalization of $2M. It is classified as a small-cap stock.
AIM ImmunoTech Inc. (AIM) does not currently pay a regular dividend.
AIM ImmunoTech Inc. (AIM) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
AIM ImmunoTech Inc. (AIM) generated $-15 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
AIM ImmunoTech Inc. (AIM) reported earnings per share (EPS) of $-30.07 in its most recent fiscal year.
AIM ImmunoTech Inc. (AIM) has a return on equity (ROE) of -388.7%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 16 years of financial data for AIM ImmunoTech Inc. (AIM), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
AIM ImmunoTech Inc. (AIM) has a book value per share of $-2.30, based on its most recent annual SEC filing.